Director, Transplant Immunology Facility Director, Cell Processing Laboratory Baylor University Medical Center TX, USA
Medhat Askar is a Professor of Pathology and Laboratory Medicine at Texas A&M College of Medicine, the Director of Transplant Immunology and Assistant Hematopoietic Cell Processing Facility Laboratory Director at Baylor University Medical Center, Dallas, TX, USA. After completing his MD and PhD (Cairo, Egypt) he trained in transplant immunology at Thomas Starzl Transplantation Institute (Pittsburgh, PA). He is board certified by the American Board of the Histocompatibility & Immunogenetics, the American Board of Medical Laboratory Immunology and the American Board of Bioanalysis. He is also a fellow of the Royal College of Pathologists (London, UK). Dr. Askar is the President of The American Board of Histocompatibility and Immunogenetics (ABHI), President-Elect of The American Society for Histocompatibility and Immunogenetics (ASHI) and a member of the National Boards of Directors of United Network for Organ Sharing (UNOS) and Organ Procurement and Transplantation Network (OPTN). He is also a Councilor to The Transplantation Society (TTS) representing North America, the Co-Chair of TTS Education Committee and a project leader for the Next Generation Sequencing (NGS) in the 18thInternational HLA and Immunogenetics Workshop that will be held in Amsterdam, Netherlands in 2021. Dr. Askar is a member of the Laboratory Practice Committee of the International Society of Cell and Gene Therapy and a principal Investigator on a number of study protocols through the Center for International Blood and Marrow Transplant Research (CIBMTR).
Professor and Chairman Institute of Transfusion Medicine and Transplant Engineering,Hannover Medical School, Hannover, Germany
Rainer Blasczyk is Full Professor of Transfusion Medicine and Head of the Institute of Transfusion Medicine and Transplant Engineering at Hannover Medical School (MHH), Hannover, Germany since 1998 as well as board member of the Transplantation Center at Hannover Medical School since 2019. He graduated in medicine from the Universities Bochum and Essen before completing postgraduate training at the Universities of Marburg, Essen, Duesseldorf and Berlin, where he started to work on Molecular Immunogenetics in 1993. After being appointed to his current position he initiated the research on transplant engineering. Professor Blasczyk has a long-term research interest in solid organ transplantation and transplantation immunology with a main focus on transplant tolerance and transplant engineering. His work centers around the alloimmune response in organ transplantation and therapeutic interventions to combat rejection and infection. This includes cellular and humoral immunotherapy as well as genetic and transplant engineering approaches to achieve transplantation tolerance. Professor Blasczyk is founder and chairman of the Immunotherapy Foundation. He has been a member of the Advisory Board on Blood Products of the German Ministry of Health, President of the German Society of Immunogenetics (DGI) and the German Society of Transfusion Medicine and Immunohematology (DGTI) as well as a Board Member of the European Society of Immunogenetics (EFI).
Director, Eurotransplant Reference Laboratory, Leiden, The Netherlands
Frans Claas, Ph.D, is director of the Eurotransplant Reference Laboratory and professor “Immunogenetics of transplantation” at the Leiden University Medical Center in Leiden, the Netherlands. The main topics of his current research are the differential immunogenicity of HLA mismatches in clinical transplantation and the immunology of pregnancy as a model for transplantation tolerance. The studies of his research group have generated more than 500 papers in peer-reviewed journals. He was the initiator of a special program within Eurotransplant to enhance transplantation of highly sensitized renal transplant patients on basis of acceptable HLA mismatches. He is an active member of different professional societies as reflected amongst others by his past-presidency of the European Federation for Immunogenetics (EFI) and past-membership of the Board of the American Society for Histocompatibilty and Immunogenetics (ASHI). He is an editor-in chief of Transplant Immunology.
Associate Professor in Nephrology, School of Medicine, Aristotle University of Thessaloniki, Greece
Pantelis Sarafidis, MD, MSc, PhD is an Associate Professor in Nephrology in Aristotle University of Thessaloniki, and Consultant in Nephrology in Hippokration Hospital, Thessaloniki Greece. He is the Head of the ESH Hypertension Excellence Center in this hospital. His research activities are focused on hypertension, CVD in patients with CKD, diabetic nephropathy, AKI, and polycystic kidney disease. He has authored more than 240 articles in peer-reviewed international medical journals and book chapters in international textbooks, and performed more than 200 lectures in national and international meetings in the areas of Nephrology, Hypertension and related fields. He is currently a reviewer for more than 60 international medical journals. Dr Sarafidis has received several awards and grants from national and international Medical Societies for his research activities.
Servicio de Nefrología e Hipertensión, Hospital U niversitario Fundación Jiménez Díaz, Madrid, SPAIN
Alberto Ortiz, MD, PhD is Chief of Nephrology at IIS-Fundacion Jimenez Diaz, Professor of Medicine at Universidad Autonoma de Madrid, Secretary of the EURECA-m working group of the ERA-EDTA, member of EUTOX and of the Spanish renal research network (REDINREN) and editorial board member at the Journal of the American Society of Nephrology. He studied Medicine at Universidad Autonoma de Madrid, specialized in Nephrology at Fundacion Jimenez Diaz and was a Post-Doctoral research fellow at the University of Pennsylvania (1992-1994) before returning to Fundacion Jimenez Diaz as senior researcher and later as staff nephrologist. Current h-index is 36. Research interests include the pathogenesis and treatment of acute kidney injury, diabetic nephropathy, proteinuric chronic kidney disease, vascular injury in kidney disease and Fabry disease.